3月13日 - ** 总部位于爱尔兰的商业阶段生物技术公司Trinity Biotech的TRIB.O股价盘前上涨8.7%至0.73美元
** 该公司称将加强 (link)，专注于其连续血糖监测(CGM) 技术
** 公司表示，全面转型计划的成功实施有望推动近期盈利能力的提高
** 公司还任命巴克莱银行为其独家财务顾问，以支持战略调整
** 截至周三收盘，该股今年迄今已下跌 22.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.